• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom stock rises after hours on raised 2023 guidance, $500M share repurchase program

October 26, 2023 By Sean Whooley

Dexcom updated logoDexcom (Nasdaq:DXCM) shares got a massive boost on third-quarter results that came in well ahead of the consensus forecast.

The San Diego-based continuous glucose monitor (CGM) maker also announced a $500 million share repurchase program in conjunction with its third-quarter results. The repurchase program follows a $1 billion senior convertible note offering this year, plus a 4-for-1 reverse stock split executed last year.

Shares of DXCM skyrocketed nearly 10% at $88.80 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down nearly 2%.

Also read: How automated insulin delivery integration drives Dexcom CGM forward

Dexcom posted profits of $120.7 million, or 29¢ per share, on sales of $975 million for the three months ended Sept. 30, 2023. The company recorded a 19.3% bottom-line gain on sales growth of 26.7%.

Adjusted to exclude one-time items, earnings per share totaled 50¢. That landed 16¢ ahead of expectations on Wall Street. Dexcom also beat the sales forecast as analysts projected $939.2 million in revenue.

“Our teams executed incredibly well in the third quarter, delivering solid financial results while further advancing global access to Dexcom CGM,” said Kevin Sayer, Dexcom chair, president and CEO. “Our continued momentum has left us in a great position to again raise our full-year revenue and margin guidance and finish a strong 2023.”

Dexcom increased its sales guidance to a range between $3.575 billion and $3.6 billion (23%-24% growth) for 2023. That ticks up from the previous range of $3.5 billion to $3.55 billion. The company also projects an adjusted gross profit margin of approximately 64%.

The analysts’ view on Dexcom

BTIG analysts Marie Thibault and Sam Eiber say the repurchase program can help offset dilution from the maturing 2023 notes that remain. They maintained a “Buy” rating for the company with optimism in its CGMs, despite the growing popularity of GLP-1s.

“Management emphasized they are extremely bullish on their long-term business as well; we like this opportunity to buy back shares at what we view as a major discount,” they wrote. “Yet again we are moving our DXCM forecasts higher. We remain confident in the long-term broad appeal of CGMs even in this evolving therapy landscape.”

They said the company’s earnings call had “refreshingly little focus on the GLP-1 debate.” GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

After hosting a call with a diabetes expert, BTIG analysts even went as far as to say GLP-1s shouldn’t have a massive impact on insulin pumps. What’s more, the drug class could even provide a continuous glucose monitor (CGM) boom.

Abbott also recently shared data to back up this notion, too. The company sees GLP-1s as a potential modest accelerator for its FreeStyle Libre CGM product family.

Dexcom updated its analysis of third-party payor data through August 2023, noting that the growing use of CGMs within Type 2 patients starting GLP-1 therapy is even more pronounced with the latest generation of drugs.

“This may be because of the high potency of these newest drugs, interest in assessing the effect of the drugs, and using CGM as a tool to encourage behavior change to support long-term improvement,” the analysts said.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS